EMA Authorised: Rybelsus (semaglutide) — Novo Nordisk A/S

View source ↗

Summary

The European Medicines Agency authorised Rybelsus (semaglutide) by Novo Nordisk A/S for the treatment of Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Rybelsus (semaglutide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novo Nordisk A/S. Decision date: 26/03/2026